Revance Therapeutics (RVNC) Misses Q1 EPS by 3c

Revance Therapeutics (NASDAQ: RVNC) reported Q1 EPS of ($0.94), $0.03 worse than the analyst estimate of ($0.91). Revenue for the quarter came in at $25.3 million versus the consensus estimate of $24.01 million.

For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• BIG3 Basketball to go public via Graf Global merger at $290 million
• United Community Banks sells equipment finance unit for $1.9 billion